We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice.
In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.
Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact [email protected] or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/
---
Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message
Podden och tillhörande omslagsbild på den här sidan tillhör Certara Evidence & Access. Innehållet i podden är skapat av Certara Evidence & Access och inte av, eller tillsammans med, Poddtoppen.
